Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 3 Randomized Double-blind Trial of Maintenance With Niraparib Versus Placebo in Patients With Platinum Sensitive Ovarian Cancer.

NCT01847274 is registered in ClinicalTrials.gov with Tesaro, Inc. as lead sponsor.

NCT NCT01847274
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT01847274 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 3 Randomized Double-blind Trial of Maintenance With Niraparib Versus Placebo in Patients With Platinum Sensitive Ovarian Cancer.
Lead sponsor
Tesaro, Inc.
Phase
Phase 3
Overall status
Completed
Start date
June 21, 2013
Completion date
December 26, 2021
Enrollment
596 (actual)
Sites
112

Conditions

As the registry lists them; a condition with its own page is linked.

ovarian neoplasms, platinum sensitive ovarian cancer